CTHRC1 Protein (His Tag)

Collagen Triple Helix Repeat-Containing Protein 1

CTHRC1 / NMTC1 Protein Product Information

• Synonym: CTHRC1
• Protein Construction: A DNA sequence encoding the human CTHRC1 ( NP_612464.1 ) ( Met 1- Lys 243 ) was fused with a polyhistidine tag at the C-terminus
• Source: Human
• Expression Host: Human Cells

CTHRC1 / NMTC1 Protein QC Testing

• Purity: > 95 % as determined by SDS-PAGE
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Ser 31
• Molecular Mass: The recombinant human CTHRC1 consists of 224 amino acids and has a predicted molecular mass of 24.5 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rh CTHRC1 is approximately 28-33 kDa due to glycosylation
• Formulation: Lyophilized from sterile PBS , pH 7.4
• SDS-PAGE: CTHRC1 protein

CTHRC1 / NMTC1 Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

CTHRC1 / NMTC1 Protein Description

Collagen triple helix repeat-containing protein 1, also known as Protein NMTC1, and CTHRC1, is a secreted protein that is glycosylated and highly conserved from lower chordates to mammals. CTHRC1 expression was not detectable in normal arteries. However, on injury it was transiently expressed by fibroblasts of the remodeling adventitia and by smooth muscle cells of the neointima. It was also found in the matrix of calcifying human atherosclerotic plaques. A short collagen motif with 12 Gly-X-Y repeats appears to be responsible for trimerization of the CTHRC1 protein and this renders the molecule susceptible to cleavage by collagenase. CTHRC1 overexpression caused a dramatic reduction in collagen type I  mRNA and protein levels. CTHRC1 has many novel biochemical activities. It is the downstream target of bone morphogenetic protein-2 (BMP-2) in osteochondroprogenitor-like cells. CTHRC1 increases bone mass as a positive regulator of osteoblastic bone formation and offers an anabolic approach for the treatment of osteoporosis. CTHRC1 expression in vascular cells regulates transforming growth factor beta responsiveness, thereby impacting transforming growth factor beta target genes, including collagens. The ability of CTHRC1 to reduce collagen deposition by inhibition of Smad2/3 activation could have major clinical applications in the fields of vascular disease, repair, and fibrosis.

References

1. Pyagay,P. et al., 2005, Circ Res. 96 (2): 261-8.
2. LeClair, R. et al., 2007, Trends Cardiovasc Med. 17 (6): 202-5.
3. Kimura, H. et al., 2008, PLoS One. 3 (9): e3174.
4. Leclair, RJ. et al., 2008,  Arterioscler Thromb Vasc Biol. 28 (7): 1332-8.